Physician profile
John J Inzerillo
NPI 1164404422
$5,064.58
in general payments reported to CMS, 2019-2025
43 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,865 · 2020: $1,776 · 2021: $250 · 2022: $375 · 2023: $239 · 2024: $250 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741 · Education: $58.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.11 |
| Education | $58.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $945.84 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $541.99 | 2019-2025 | Opdivo, Pomalyst, Opdualag |
| Dendreon Pharmaceuticals LLC | $353.92 | 2019-2022 | |
| Genentech USA, INC. | $336.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $316.02 | 2019-2025 | |
| Seagen INC. | $273.30 | 2019-2022 | |
| Pfizer INC. | $267.04 | 2019-2024 | |
| Janssen Biotech, INC. | $263.30 | 2019-2025 | Erleada |
| Merck Sharp & Dohme LLC | $187.09 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $175.37 | 2019-2025 | Imfinzi |
| Lilly USA, LLC | $125.88 | 2019-2022 | |
| Amgen INC. | $124.00 | 2019-2024 | Lumakras |
| Genzyme Corporation | $99.62 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $97.79 | 2019 | |
| Celgene Corporation | $83.78 | 2019-2024 | Reblozyl |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Inzerillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.